NCT03809624: Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma

NCT03809624
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be resistant to or have relapsed on anti-PD-1, anti-PD-L1, and/or anti-CTLA4 therapy for those tumor types for which checkpoint inhibitors are FDA approved (e.g. TNBC)
Exclusions: Patients with known, active, untreated, unstable central nervous system (CNS) metastases or leptomeningeal disease – see trial for details
https://ClinicalTrials.gov/show/NCT03809624

Comments are closed.

Up ↑